Skip to content
Surgical Oncology

Esophagectomy - Esophagus Removal Surgery

About This Department

 
Surgical Oncology

Esophagectomy removes the cancer-bearing part of the esophagus and rebuilds the swallowing tube from the stomach. Treatment before surgery comes first for deeper tumors, and keyhole surgery halves lung complications.

Esophagectomy is the main curative operation for cancer of the esophagus and the junction with the stomach. This page explains what the operation involves, who is a candidate, which treatment comes first, when surgery can wait after a complete response, how open, minimally invasive and robotic surgery compare, how the join is protected and what to send for a free review.

54.5%
Three-year survival free of recurrence after FLOT chemotherapy and surgery, against 39.0% after chemoradiotherapy, in the ESOPEC trial
54%
Fewer lung complications after minimally invasive esophagectomy than after open surgery, across randomized trials
43%
Patients with a complete response who never needed esophagectomy under active surveillance in the SANO trial
Free
Free consultation on your reports and scans before you book

What esophagectomy involves

The surgeon removes the diseased esophagus and turns the stomach into a new swallowing tube.
1
Abdomen
The stomach is freed and shaped into a narrow tube, and the lymph nodes around it come out.
2
Chest
The esophagus and the nodes beside it come out through the right chest.
3
The join
In an Ivor Lewis operation the new tube joins the remaining esophagus inside the chest. In a McKeown operation the join sits in the neck.
4
Feeding tube
A thin tube into the small bowel feeds you while the join heals.

Who is a candidate

Surgery suits cancers that have not spread beyond the esophagus and nearby lymph nodes, in patients fit enough for an operation in the chest and abdomen. Age alone rules no one out.

  1. Adenocarcinoma of the lower esophagus or the junction with the stomach
  2. Squamous cell carcinoma after chemoradiotherapy, when the tumor remains or returns
  3. High-grade dysplasia or early cancer that endoscopic treatment cannot clear
  4. Selected benign conditions, such as a stricture that no dilation can open
Heart and lung fitness tests decide whether a patient can withstand the operation.

The treatment path

1
Diagnosis
Endoscopy, biopsy, CT and PET-CT stage the tumor.
2
Treatment before surgery
Chemotherapy over eight weeks or chemoradiotherapy over five weeks shrinks the tumor and treats cells that have already spread beyond it.
3
Restaging
Repeat scans and endoscopy show the response.
4
Surgery
Four to eight weeks after the last treatment.
Every step runs through the tumor board.

When surgery can wait

Some tumors disappear completely after chemoradiotherapy.

In the Dutch SANO trial, 309 patients with no tumor left on biopsies, endoscopic ultrasound and PET-CT after chemoradiotherapy received either regular checks with surgery only if cancer returned, or standard surgery. Five-year survival reached 50 percent with surveillance and 54 percent with surgery, a difference that did not reach statistical significance, and 43 percent of the surveillance group never needed an esophagectomy. Distant spread ran higher under surveillance, 46 against 29 percent. Swallowing, breathing and energy were better at six months for patients under surveillance, and swallowing stayed better at two years. Squamous cell cancer and adenocarcinoma gave similar results. Choice matters. Surveillance suits patients who accept frequent checks and understand that an operation, if needed, comes later and sometimes after the cancer has spread, so the tumor board reviews each response with you before you decide, and the decision can change at any visit with your surgeon and oncologist both present.

Surveillance means endoscopy and PET-CT every few months, and an operation the moment cancer reappears.

Chemotherapy or chemoradiotherapy first

For adenocarcinoma, FLOT chemotherapy around surgery now leads.

The German ESOPEC trial randomized 438 patients with esophageal adenocarcinoma to FLOT chemotherapy before and after surgery or to the CROSS regimen of chemoradiotherapy before it. Among the 371 who reached surgery, three-year survival free of recurrence was 54.5 percent after FLOT and 39.0 percent after CROSS, a hazard ratio of 0.67. Fifteen points. The gain came from fewer distant recurrences, 31.5 against 47.2 percent, while recurrence near the original tumor stayed the same. Squamous cell cancer, the type common in Asia and the Middle East, still receives chemoradiotherapy.

This table scrolls sideways on a narrow screen. Swipe or drag to see every column.

FLOT against CROSS in the ESOPEC trial
Measure FLOT CROSS
Patients randomized 221 217
Reached surgery 86.9% 82.5%
Three-year survival free of recurrence 54.5% 39.0%
Distant recurrence at three years 31.5% 47.2%
Local recurrence at three years 20.2% 17.4%

Tests before surgery

  1. Endoscopy with biopsy and endoscopic ultrasound
  2. CT of the chest and abdomen, and a PET-CT
  3. Breathing tests and an echocardiogram
  4. A nutrition assessment, with a feeding plan if you have lost weight
  5. Blood tests and a review of your medications
Stopping smoking and walking daily before surgery lower the risk of pneumonia.

Open, minimally invasive or robotic

Across eight randomized trials with 1,776 patients, minimally invasive and robotic esophagectomy cut lung complications by more than half against open surgery, relative risks of 0.46 and 0.48, with shorter hospital stays and the same leak rate, deaths in hospital and cancer clearance. Lungs benefit most. A review of 16 randomized trials with 2,729 patients found higher death rates within 30 days after open surgery, a relative risk of 1.84, and better physical function a year later after minimally invasive operations. Three randomized trials with 549 patients found robotic and conventional approaches level on leaks, pneumonia and complete resection.

On a phone, slide this table sideways to read all of its columns.

Minimally invasive and robotic against open esophagectomy
Measure Finding
Lung complications Less than half the risk, relative risks 0.46 and 0.48
Hospital stay Shorter
Anastomotic leak No difference
Deaths within 30 days Higher after open surgery, relative risk 1.84
Survival Comparable
The surgeon picks the route that gives a complete resection for your tumor.

The join and the first weeks

A leak from the join between the stomach tube and the esophagus ranks among the most serious complications. Prevention starts in the operating room. Across nine studies with 2,227 patients, wrapping the join in a flap of omentum, the fatty apron of the abdomen, cut leaks by two thirds, a risk ratio of 0.32, and one leak was prevented for every 13 patients wrapped.

  1. One or two nights in intensive care
  2. Feeding through the bowel tube from the first day
  3. A check of the join before you drink
  4. Liquids, then soft food, then small solid meals
  5. Discharge once you eat enough and walk the corridor
Sleeping with the head of the bed raised keeps stomach contents from rising.

Treatment after surgery

When cancer cells remain in the specimen after chemoradiotherapy and surgery, a year of nivolumab immunotherapy follows. The CheckMate 577 trial showed longer survival free of disease. A Dutch national registry later compared 311 matched pairs of patients with and without nivolumab and found two-year survival of 66.8 against 58.8 percent, a hazard ratio of 0.75. A real-world gain. After FLOT, the remaining four cycles of chemotherapy come once you recover from surgery.

Drag sideways on a narrow screen to see the whole table.

Adjuvant nivolumab in Dutch practice
Measure Nivolumab No nivolumab
Matched patients 311 311
Two-year survival 66.8% 58.8%
Hazard ratio for death 0.75 Reference
Your oncologist at home can give nivolumab every two or four weeks.

Your time in Istanbul

One published Istanbul package for esophageal resection, at Memorial Şişli, lists seven days in hospital. Airfare and hotel sit outside it. After esophagectomy for cancer, we plan two to three weeks in the city, longer when a complication slows recovery. Patience pays.

1
Days one and two
Scans, breathing tests, a nutrition review and the tumor board.
2
Surgery
Then one or two nights in intensive care.
3
Ward week
Tube feeding, the check of the join, first liquids and walking.
4
Before the flight
Soft food, the feeding plan, the pathology report and the treatment plan for home.
Flights wait until you eat by mouth.

A single coordinator handles your trip on WhatsApp, from the first message to the last follow-up call once you are back home. The team speaks English, Arabic, French, Russian, Serbian, Romanian and Spanish, and an interpreter covers other languages. A relative may sleep in your room on the companion bed. The international patients office books a hotel close to the hospital, collects you at the airport and drives you to every appointment, a female surgeon operates on request where the rota allows, and the kitchen serves halal, vegetarian and diabetic meals, with a prayer room in the building. Your visa invitation letter leaves ten days before you travel. Swallowing stays slow in the first weeks, so we pack soft snacks and liquid feeds for the journey, arrange wheelchair help at both airports and ask you to walk the aisle every hour against clots. Back home, your oncologist and dietitian receive the reports in English, and the surgeon checks your weight and swallowing by video call.

Call us the same day for fever, chest or neck pain, a new cough after drinking, vomiting, difficulty swallowing that gets worse, or calf pain. Any hour.


What the cost depends on

A firm figure follows the free review of your scans.

Cost depends on open, minimally invasive or robotic surgery, an Ivor Lewis or McKeown operation, any chemotherapy or chemoradiotherapy given in Istanbul, the nights in intensive care and on the ward, and the feeding tube and nutrition support afterwards. The written quote arrives after the review. It names every item it covers, so treatment given at home before or after surgery stays outside it.

Scroll the table left and right on a small screen to see each column.

What moves the cost
Factor Effect
Robotic surgery Higher operating room cost
Minimally invasive surgery Shorter stay
Chemotherapy in Istanbul Adds cycles and weeks
Complications Extra nights and procedures
Feeding support Formula and dietitian visits

Esophagectomy FAQ

Your endoscopy report, biopsy and scans shape the plan before you travel.
Can I eat normally without an esophagus?
Yes, in smaller meals. The stomach tube carries food down, so you eat five or six small meals a day and avoid lying flat after eating.
Do I need chemotherapy before surgery?
For tumors beyond the inner layers, yes. Adenocarcinoma receives FLOT, and squamous cell cancer receives chemoradiotherapy.
Can I avoid surgery?
When chemoradiotherapy leaves no visible tumor, active surveillance is an option. In SANO, 43 percent of the surveillance group never needed an esophagectomy.
Will my voice change?
A nerve to the voice box runs close to the esophagus and can be bruised, leaving a hoarse voice that recovers over weeks in the large majority.
What should I send for a free review?
Endoscopy and biopsy reports, CT and PET-CT images, any endoscopic ultrasound, details of treatment so far and a list of medications. A surgeon replies with the treatment path, the type of operation and the expected stay, at no charge and with no obligation to travel.
Scan images on a download link or disc let the surgeon plan before you travel.

References

  1. Panday SSGG, van der Wilk BJ, Lagarde SM, et al. Active surveillance versus standard surgery after neoadjuvant chemoradiotherapy for oesophageal cancer: long-term results of a cluster-randomised controlled trial (SANO). Ann Oncol. 2026. doi:10.1016/j.annonc.2026.10.1290.
  2. Gangaram Panday SSG, van der Wilk BJ, Eyck BM, et al. Health-related quality of life of patients undergoing active surveillance versus standard surgery for oesophageal cancer (SANO trial). Br J Surg. 2026;113(1). doi:10.1093/bjs/znaf286.
  3. Hoeppner J, Schmoor C, Brunner T, et al. Recurrence patterns of esophageal adenocarcinoma in the phase III ESOPEC trial comparing perioperative chemotherapy with preoperative chemoradiotherapy. J Clin Oncol. 2025;43(32):3451-3456.
  4. Aiolfi A, Cammarata F, Bonitta G, Bona D, Bonavina L. Open, hybrid, minimally invasive, and robotic-assisted transthoracic esophagectomy for cancer: a network meta-analysis of randomized trials. Int J Surg. 2025;111(11):8503-8514.
  5. Dunne N, Davey MG, Donlon NE. Comparing outcomes following open, hybrid, minimally invasive, and robotic-assisted esophagectomy: a systematic review. Eur J Surg Oncol. 2026;52(1):110531.
  6. Mirza W, Khan ME, Iqbal H, et al. Robot-assisted (da Vinci) versus conventional esophagectomy for resectable esophageal cancer: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials. J Robot Surg. 2025;19(1):742.
  7. Fouad M, Sourial K, Ibraheim S. Impact of omental flap reinforcement on anastomotic leak after esophagectomy: updated evidence incorporating minimally invasive and high-volume contemporary series. Dis Esophagus. 2026;39(3). doi:10.1093/dote/doag061.
  8. Verhoeven RHA, Kuijper SC, Slingerland M, et al. Adjuvant nivolumab after chemoradiotherapy and resection for patients with esophageal cancer: a real-world matched comparison of overall survival. Int J Cancer. 2026;158(5):1292-1301.

Editor's note

Written by the Biruni Hospital medical editorial team. Reviewed by Prof. Dr. Mustafa Teoman YANMAZ, Medical Oncology.

Last updated:

Related Treatments

View All